Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial.
Persistent or increasing breast density linked to higher cancer risk
Identifying patterns in breast density changes can improve breast cancer risk prediction, emphasizing the importance of longitudinal assessments in screening.
January 6, 2025